Taking
nature’s lead in antimicrobials

 
13/04/2017

NovaBiotics contribution to ECCMID 2017

NovaBiotics, the clinical-stage anti-infectives biotechnology company, will be presenting five posters/e-posters and speaking at the at the 27th European Congress of Clinical Microbiology and Infectious Diseases’ (ECCMID) Pipeline Corner symposium.  The team, led by CEO Dr Deborah O’Neil and accompanied by Daniel Smith, Dr Douglas Fraser-Pitt, Dr Laura Katvars and Dr Derry Mercer, will be presenting an update to NovaBiotics’ Cysteamine and novel modified antimicrobial peptide (AMP) platforms.  Pipeline Corner is a symposium for invited innovative companies to provide an overview of their R&D pipelines and present recent advances in early-stage programmes.   

 

Dr Deborah O’Neil said “NovaBiotics is on the front line of discovery and development of novel solutions for the global antimicrobial resistance pandemic.  We have developed two unique platforms which leverage the immune system’s innate defence mechanisms.  Product candidates from both platforms are already in advanced stages of clinical development. Our unique technological approach has significant potential and I look forward to sharing developments with colleagues and peers at ECCMID 2017”.

 

The presentation, which will take place on Sunday 23 April at 12:30PM in Foyer E, will provide an overview of the platforms and review potential demonstrated in development thus far. A link to the presentation can be found here. NovaBiotics Presentation April 2017          

The other members of the NovaBiotics team will present more detail on both the Cysteamine and antimicrobial platforms and also the company’s clinical stage anti-infective candidates in their posters and brief e-poster presentations throughout the rest of the conference, programme for which can be found here http://www.eccmid.org/ and the full presentation schedule is as follows:

Symposium

Presenter(s)

Presentation

Date

Time

Location

Pharmacoepidemiology, Improved Prescribing and Antibiotic Stewardship

Mr Daniel Smith

Cysteamine has a broad spectrum antimicrobial utility against a wide variety of emerging pathogens of cystic fibrosis associated lung disease

Saturday 22 April - Tuesday 25 April

08:45-15:30

ePoster Viewing Area

New Antibiotics - New Approaches

Dr Douglas Fraser-Pitt

Cysteamine As An Antibiotic Resistance Breaker

Sunday 23 April

13:30-14:30

ePoster Area 3

Drugs against Gram-Positives-More Data

Dr Laura Katvars

Novarifyn, a novel antimicrobial peptide rapidly active against multi-drug-resistant Staphylococcus aureus and Acinetobacter baumannii

Monday 24 April

12:30-13:30

Paper Poster Area

Antifungal Drugs and Treatment I

Dr Laura Katvars & Dr Derry Mercer

NP339 as a novel approach against respiratory fungal infections & Antifungal activity of NP339 in vivo in respiratory models of fungal infection

Tuesday 25 April

12:30-13:30

Paper Poster Area

About NovaBiotics

NovaBiotics is a leading clinical-stage biotechnology company focussed on developing first-in-class antibacterial and antifungal solutions to combat the global Antimicrobial Resistance pandemic.  The Company’s has both a classic and novel approach to combatting AMR, both of which leverage the innate immune system’s defence mechanisms.  The Company’s robust technology has been validated through successful development, from concept to clinic, of its two lead products.

 

NovaBiotics is a privately held company founded in 2004 by CEO Deborah O’Neil.  The company is based in Aberdeen, UK and is led by a strong and experienced management team supported by first class key opinion leaders and scientific advisers.